|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Cambridge-based Vericel surged late Tuesday after the FDA approved a treatment for knee cartilage repair that involves harvesting a patient’s own cells. The FDA said it had approved Vericel's Maci, a product that collects and expands a patient’s cells — called autologous cells — then places them onto a collagen membrane that is implanted over the area where tissue was removed. Vericel has two other FDA-approved products, skin graft treatment Epicel and another knee cartilage repair product called Carticel.
Aastrom Biosciences, Inc. , a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to ...
We rates shares of Aastrom Biosciences, Inc. (ASTM) a 'Buy' and are adjusting our target to $6.50 per share. Based on industry-average multiples, we see Aastrom's stock doubling in 2015. On November 13, 2014, Aastrom Biosciences reported financial results for the quarter of 2014 ending September 30, 2014. Results in the quarter included a full quarter of operations for the recently acquired Cell Therapy and Regenerative Medicine ("CTRM") business from Sanofi (SNY), previously known as Genzyme Biosurgery Aps.